Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from ProQR ( (PRQR) ) is now available.
On May 12, 2026, ProQR reported first-quarter 2026 results, highlighting progress across its Axiomer-based pipeline and a solid cash position of €81.1 million, which it says supports operations into mid-2027. The company remains loss-making, with a Q1 net loss of €13.4 million amid steady R&D spending and rising administrative costs.
The lead program AX-0810 stayed on track to deliver target engagement data in healthy volunteers in the second quarter of 2026, as ProQR refocused Phase 2 development on biliary atresia and prepared an investigator-initiated pediatric trial in China for initial data in the first half of 2027. Management also moved to broaden its pipeline and platform, advancing additional RNA editing candidates toward the clinic, deepening AI-enabled discovery through a partnership with Ginkgo Bioworks and a new AI advisory board, and strengthening governance with the nomination of Boehringer Ingelheim executive Lykke Hinsch Gylvin to the board, all aimed at bolstering its position in next-generation RNA therapeutics.
The most recent analyst rating on (PRQR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
The score is held back primarily by weak financial performance (persistent losses and renewed heavy cash burn) and a negative P/E that underscores lack of profitability. Technicals provide some support due to improving price momentum above key moving averages.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics N.V. is a clinical-stage biotechnology company developing transformative RNA therapies based on its proprietary Axiomer RNA base editing platform. The Dutch-U.S. group focuses on using ADAR-mediated RNA editing to correct mutations or modulate protein expression in rare and prevalent diseases with high unmet medical need.
Average Trading Volume: 547,211
Technical Sentiment Signal: Sell
Current Market Cap: $166.5M
Find detailed analytics on PRQR stock on TipRanks’ Stock Analysis page.